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his is the ﬁrst of a series of articles
based on presentations at the Amer-
ican Diabetes Association (ADA)
70th Scientiﬁc Sessions held on 25–29
June2010inOrlando,Florida,pertaining
to thiazolidinedione(s) (TZD) and to ap-
proaches to insulin treatment for type 2
diabetes. At a symposium on the role of
TZD, Thomas Buchanan (Los Angeles,
CA) discussed the b-cell beneﬁts of TZD
andtheiractiontoslowtheprogressionof
diabetes. Clinically, the agents increase
body fat, acting to increase appetite, but
making fat “behave better” and leading to
a reduction in insulin resistance and im-
proved glycemia. TZDs alter circulating
lipids, lower blood pressure, reduce cor-
onaryarteryrestenosisafter percutaneous
intervention, and decrease ultrasono-
graphic progression of carotid and coro-
nary artery disease but increase the risk of
distal extremity (and perhaps other skel-
etal) fracture and of congestive heart fail-
ure. They may alter the risk of acute
occlusive events.
Toset the stage for understanding the
TZD effect on b-cell function, Buchanan
reviewed the hyperbolic relationship
betweeninsulinsensitivityandinsulinse-
cretion. The product of the two parame-
ters, the disposition index, decreases as
diabetes develops. Cross-sectional data
suggest that, as the fasting glucose increa-
sesfromunder 100 to 100–140andagain
from 140 to 180 mg/dL, there is particu-
larly great deterioration in b-cell func-
tion, with lesser deterioration as glucose
levels increase further (1).
Buchanan reviewed his studies, com-
paring those who had developed diabetes
with those who had not after having had
gestational diabetes. There was a non-
linear relationship between reduction in
b-cell function and elevations in glucose
levels, with greater reduction leading to
the development of diabetes (2). Al-
though he pointed out that higher blood
glucose, lesser b-cell function, and worse
degrees of insulin resistance “doesn’ta c -
tuallytellyouwhytheydevelopdiabetes,”
Buchanan reviewed further analysis
showing weight gain to be the strongest
predictor of diabetes, mediated by reduc-
tions in insulin sensitivity on euglycemic
clamp studies and, perhaps more impor-
tantly, by changes in cytokines, including
decreases in adiponectin and increases in
C-reactive protein (3). Individuals with
impaired fasting glucose and, even more
so, with diabetes have exhibited a reduc-
tion in b-cell mass at autopsy (4), and
there is a direct relationship between
b-cell mass and function in islets of indi-
viduals with type 2 diabetes (5). Type 2
diabetes then develops in the setting of
b-cell failure to compensate for decreased
insulinsensitivity,leadingtoslowlyaccel-
erating elevations in blood glucose.
In this context, one can suggest a
model of the effects of TZD. In diabetes
prevention trials, the continuous process
of worsening glycemia is arbitrarily di-
chotomized. Buchanan suggested that
preventionofdiabetescouldconceptually
involve either 1) a reduced rate of pro-
gression/slope of the increase in glucose
levels or 2) a change at the starting point,
which could be regarded as masking pro-
gression.Intheﬁrstoption, therearepro-
gressively fewer cases with intervention,
but if the treatment is stopped, the inter-
vention and control groups will develop
diabetes in parallel. In the second option,
the two groups develop diabetes in a par-
allelfashionbutwithalagintheinterven-
tion group and with relatively rapid
return tocontroldiabetesprevalenceafter
withdrawal of intervention. He suggested
that TZD seem to reduce the rate of dis-
ease progression and that, after with-
drawal of these agents, diabetes rates do
not converge in intervention and control
groups.“Youcanactually,”hesaid,“arrest
the decline in b-cell function,” with the
level of insulin secretion the strongest
predictor of those who will develop dia-
betes.IntheTroglitazoneinPreventionof
Diabetes (TRIPOD) study (6), pioglitazone
(PGZ) was given after withdrawal of trogli-
tazone (7), the overall effect of the agents
appearing to be “b-cell unloading.”
In the Diabetes REduction Assess-
ment with ramipril and rosiglitazone
Medication (DREAM) and Actos Now
for Prevention of Diabetes (ACT NOW)
studies, diabetes development rates grad-
ually diverged. The lifestyle intervention
intheDiabetesPreventionProgram(DPP)
showedasimilareffect,whereastheuseof
metformin (MET) in the DPP and that of
acarbose in the Study TO Prevent Non–
Insulin-Dependent Diabetes Mellitus
(STOP-NIDDM) trial seemed to prevent
diabetes by directly reducing glycemia,
with both trials showing relatively rapid
development of diabetes after withdrawal
of treatment. In studies of patients with
existing diabetes, Buchanan suggested
that rosiglitazone (RGZ), given as mono-
therapy in A Diabetes Outcome Progres-
sion Trial (ADOPT), or in combination
with MET or a sulfonylurea (SU) in the
Rosiglitazone Evaluated for Cardiac Out-
comes and Regulation of Glycaemia in Di-
abetes (RECORD) trial, delayed rates of
progression of hyperglycemia. Buchanan
interpreted these studies to show that
T Z Dm a ys l o wt h el o s so fb-cells and stabi-
lize b-cell function. Elaborating on the no-
tion of disease stability, he suggested that
this is particularly probable early in the
course of the disease when lifestyle inter-
ventionfails;however,heraisedthecaveats
that approximately one-thirdoftreated pa-
tients arenonrespondersandthat“they are
not heavier...[and] not more insulin re-
sistant.” One should then, perhaps, care-
fully assess the TZD response after 3
months. In prediabetes and early-onset di-
abetes, Buchanan suggested that their ac-
tion can be ascertained froma reduction in
the fasting insulin; however, this has not
been assessed in all racial/ethnic groups.
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PERSPECTIVES ON THE NEWSFurthermore, the long-term microvascular
outcomesof diabetes prevention with TZD
are not known and there remain questions
pertaining to side effects.
Andrew Gray (Auckland, New
Zealand) discussed the effects of TZD
on bone (8). Between 5 and 10% of the
skeletonisremodeledactivelyatanygiven
time; in osteoporosis, either osteoclast
function is increased or osteoblast func-
tion is decreased. Osteoblasts are derived
from mesynchymal precursors, with per-
oxisome proliferator–activated receptor g
(PPARg) increasing precursor maturation
asadipocytes.Boneresorptionisincreased
by the TZD in vitro (9). TZD-induced re-
duction in bone mass involves decreased
bone formation in younger animals and
increased resorption in older animals.
Furthermore, Gray stated that mice with
heterozygous deletion of PPARg have in-
creased bone formation and increased
bone mass. Speciﬁc homozygous deletion
of PPARg in the osteoclast lineage leads to
osteopetrosis (10).
In a 14-week study, RGZ decreased
the bone formation marker procollagen
type I NH2-terminal propeptide in healthy
postmenopausal women, without ac-
companying decline in serum b-COOH-
terminal telopeptide of type I collagen, a
marker of bone resorption, and hip and
spine bone mineral density decreased by
1–2% (11); a number of other authors
have reported similar ﬁndings (12), with
evidence of change in bone biomarkers in
ADOPT(13)andofincreased fracture risk
in the RECORD trial (14). The increased
fracture risk particularly affects the distal
skeleton (15), but recent studies suggest
increased hip fracture with these agents as
well (16,17). Furthermore, there may be
increasing fracture risk in hip and spine
over time in both men and in women
(18). In a study presented at the ADA Sci-
entiﬁc Sessions, Bilezikian et al. (abstract
394) showedthatcomparison of MET vs.
MET plus RGZ showed reduction in
hip dual-energy X-ray absorptiometry
(DEXA)bonemineraldensityinthelatter
group. Colhoun et al. (abstract 74)
reported a “self-controlled case series” of
individuals treated with TZD, suggesting
signiﬁcantdoublingofhipfracture risk,in
both men and women, in a study with
4,730 and 2,503 individuals and years of
observation before and during TZD treat-
ment.
“The drugs are toxic to the skeleton,”
Gray concluded, recommending that
DEXA bone density measurement as
well as the use of clinical risk factor
assessment such as FRAX be conducted.
“My own feeling,” he said, “is that if esti-
mated fracture risk exceeds 10%, you
should think about not using the drugs
or...[giving agents to] protect bone.” In
the Womens’ Health Initiative, he stated
that postmenopausal hormone replace-
menttreatmentsomewhatreducedfracture
risk among women receiving TZD, but he
considered bisphosphonates to be “the
most attractive option.” The development
of selective PPAR modulators not induc-
ing bone loss would be desirable.
Phillip Home (Newcastle, U.K.) ad-
dressed the question of PPARg agonist
cardiovascular (CV) effects by asking,
“Has the dust settled? What is the effect
of the TZD on CV risk after all?”“ The
story goes back quite a long way,” hecon-
tinued. There was evidence of CV toxicity
with the PPARa agonist cloﬁbrate. The
PPARg agonist ciglitazone was found to
cause cardiac hypertrophy and ﬂuid re-
tention, combined PPARag agonists
were found to cause bladder tumors in
rodents and possibly in humans, PPARa
and PPARg agonists seemed to cause co-
lon and lung tumors, and the PPARag ag-
onist muriglitazar was reported to cause
cardiac toxicity.
RGZ and PGZ were licensed in Eu-
rope with the condition that CV studies
be conducted. The secondary prevention
PROspectivepioglitazoneClinicalTrialin
macrovascular Events (PROactive) en-
rolledindividualswithextensiveevidence
of CV disease, and RECORD recruited a
more typical diabetic population, both
starting in 2001.The results of PROactive
were reported in 2005, with the primary
end point showing a nonsigniﬁcant 10%
reduction, which was caused by an in-
crease in peripheral vascular disease
events, whereas virtually all other CV
end points were reduced by 15–20%,
with the principal secondary end point
of mortality, myocardial infarction, and
stroke signiﬁcantly reduced by 16% (P 5
0.027). “For RGZ,the situation was a little
different,” Home stated. A meta-analysis
conducted by GlaxoSmithKline (Research
Triangle Park, NC) in 2006 suggested an
increase in myocardial infarction, con-
ﬁrmed by a publication in 2007 (19), al-
though Home stated that both studies
“just reached statistical signiﬁcance” and
that an update with an additional 10 stud-
ies just released showed a nonsigniﬁcant
10% increase in events. Home observed
that theremay be an issue with “instability
of the data within these meta-analyses.”
A meta-analysis of low-quality studies of
magnesium supplementation in 1993, for
example, showed a beneﬁt in acute myo-
cardial infarction; however, the 1995
International Study of Infarct Survival
(ISIS-4) showed absolutely no beneﬁt
(20). “The randomized controlled trial
trumped meta-analysis,” Home observed,
noting that a recent meta-analysis report-
ing increased rates of malignancy with an-
giotensin receptor blockers similarly
should be considered highly speculative.
Home stated that the RECORD study
hasthenbecomethehypothesistestofthe
RGZ meta-analyses. RECORD studied
4,458 individuals with type 2 diabetes,
comparing RGZ with either MET or SU
to the combination of MET1SU (14).
The primary end point was CV death or
CV hospitalization. Full follow-up is
available for more than 80% of patients
at 7 years. Changes after randomization
didoccurintreatment,andtheyincreased
over time, but for 88% CV follow-up,
those allocated to the RGZ arm received
the agent. The likelihood ratio of the pri-
mary outcome was 0.99 (95% CI 0.85–
1.16), and “unlike PROactive,” Home
noted, “in RECORD, heart failure is in-
cluded.” With inclusion of atherosclerotic
events only, the likelihood ratio was
0.970, and with separate comparisons of
METwithRGZ vs.SU,thelikelihoodratio
was 1.01, whereas with background SU,
the ratio for RGZ vs. MET was 0.98.
“These sensitivity analyses lead you to
have great conﬁdence,” Home continued,
“that there is no difference in CV events.”
Forall-causeandCVmortality,therespec-
tive likelihood ratios were 0.86 and 0.84,
so that, although not statistically signiﬁ-
cant, “the probability is overwhelmingly
in favor of beneﬁt rather than harm as it
pertains to death.” The trial was not pow-
ered for other end points, but the likeli-
hood ratios were 1.14 for myocardial
infarction; 0.72 for stroke; 0.93 for CV
death, myocardial infarction, or stroke;
1.05 for acute coronary syndrome (ACS);
0.96 for ACS or angina; and 0.99 for ACS,
angina, or revascularization. “It’s very dif-
ﬁcult to suggest,” Home concluded, “that
there is any increase in acute coronary
events.” In contrast, there was the recog-
nized increase in likelihood of heart fail-
ure, with a likelihood ratio of 2.1.
Becauseoftheprogressionofdiabetes,
therapies change over time, so one “can
onlymakesenseoftheseforabout5years,”
Home stated, but he noted that there was
very good mortality ascertainment and
that very strict deﬁnitions of myocardial
infarction were applied. Event rates in
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that, in RECORD, the number of events
was sufﬁcient to conﬁdently state that
noninferiority was shown.Acute coronary
events were indistinguishable with RGZ
from those in patients treated with MET/
SU;recurrenteventsamongthe64patients
receiving RGZ and the 56 patients treated
with MET/SU, upon suffering their ﬁrst
myocardial infarction, were indistinguish-
able, with four deaths in each group.
Home pointed out the similarities of
RECORD to the ﬁndings of the BARI 2D
study inindividualswith proven coronary
disease,who had been receiving insulin or
SU-based vs. MET and RGZ-based treat-
ment,andsimilaritiestotheﬁndingsofthe
APPROACH intravascular ultrasound
study of patients receiving RGZ vs. glipi-
zide, with event rates of 11.7 vs. 11.2%
(21). Likewise, in both the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) trial and in Veterans Affairs
Diabetes Trial (VADT), RGZ has been
noted not to have increased risk. It is
noteworthy that stroke reduction was
found in RECORD with a likelihood ratio
of 0.72, in ADOPT with a ratio of 0.77, in
early RGZ studies with a ratio of 0.48, and
in PROactive with a ratio of 0.81. Home
showed a meta-analysis demonstrating a
signiﬁcant 25% reduction in the likeli-
hood of a stroke. He concluded that TZD
are not associated with increased CV risk
or myocardial infarction risk. Further-
more, Home said, TZD may have beneﬁt,
as opposed to harm, for death and for
stroke compared with the combination
of MET and SU.
Ian Blumer (Toronto, ON, Canada)
discussed clinical use and monitoring of
TZD,focusing onselectedaspectsoftheU.
S.guidelinesonprescribinginformationor
product monographs. “In the interests of
making the session meaningful,” he said,
he would discuss both RGZ and PGZ as a
class. The adverse effects of both TZD may
include macular edema in the eye, active
liver disease (with transaminase levels
morethan2.5-to3.0-foldabovetheupper
normal), and increased fracture rates
as previously discussed. Finally, there is
RGZ’s increased rate in myocardial infarc-
tion according to the meta-analysis (19).
Blumerstatedthat“wetalkaboutheartdis-
ease perpetually,” use of nitrates is not rec-
ommended in class 3 and class 4 heart
failure, and combined use of insulin with
RGZ is also not recommended.
Despite .14 million patients and
years of use, he said, “we still ask our-
selves if and when we should be using
drugs from this class.” There are certainly
studies showing that TZD prevent diabe-
tes,butheraised“concerns,includingun-
proven long-term efﬁcacy, adverse
effects, [and] costs.” The current ADA
standards state that “metformin should
be the only drug considered for use in di-
abetes prevention,” and Blumer recom-
mended that TZD not be used for this
purpose. He noted that TZD are not rec-
ommended as monotherapy in the ADA/
European Association for the Study of Di-
abetes consensus statement, but stated
that, in considering add-on therapy for
glycemic control, “it’sn o tam a t t e ro fi f ,
it’s a matter of when” to use a TZD. The
factors inﬂuencing his choices of add-on
therapy include efﬁcacy, durability, other
auxiliary beneﬁts, adverse effects, long-
term safety, label vs. off-label use, clinical
practice guidelines, expert opinion, cost/
coverage, and, perhaps most tellingly,
what he termed as “hassles,...the re-
sponse my patients have to medication.”
Noting that guidelines are not infallible,
he stated that TZD are considered “suit-
able, [if] not necessarily ideal,” by guide-
lines of the ADA, American Association of
Clinical Endocrinologists, National Insti-
tute for Health and Clinical Excellence,
and various agencies in Europe, Italy,
Germany, Scotland, Australia, Singapore,
and the United Arab Emirates. None of
the guidelines suggests that TZD use be
abandoned. He “anticipate[d] ongoing
concerns about TZD safety and the possi-
bility that these concerns will never be re-
solved.” Given the medicolegal issues
raised by these concerns, the develop-
ment of new drugs, and the inevitable
lack of promotion as patents expire, he
predicted that the drugs “will gradually
fade away.”
Add-ons to Insulin
Candis M. Morello (San Diego, CA) dis-
cussed choices in adding oral agents for
individuals with type 2 diabetes already
receiving insulin (22). Insulin resistance
is a major feature of the pathogenesis of
type2diabetes,withMETandTZDacting
at this level. The dipeptidyl peptidase
(DPP)-4inhibitorsreducehepaticglucose
production;theDPP-4inhibitorsandSUs
act to increase insulin secretion, and the
bile acid sequestrants and a-glucosidase
inhibitors (AGIs) act in the gut. A number
of studies have assessed the addition of
MET to treatment of patients with type 2
diabetesreceivinginsulin(23,24),showing
reduction in A1C and body weight, with
lipid beneﬁt as well. In a Turkish study
on insulin alone or in comparison with
a c a r b o s e ,M E T ,o rR G Z ,t h el a t t e rt w o
agents were particularly effective in lower-
ing levels of glucose and A1C, whereas all
agents reduced the insulin dose require-
ment (25). A number of studies have ana-
lyzedtheadditionofTZDininsulin-treated
patients (26); there seems to be particular
beneﬁt in patients with greater degrees of
insulin resistance, although weight gain,
hypoglycemia,peripheraledema,andheart
failure are adverse occurrences. The use of
DPP-4 inhibitors inconjunctionwithinsu-
lin is another potential approach, with a
study of 641 patients receiving insulin ran-
domizedto100mgsitagliptindailyvs.pla-
ceboshowinga0.6%reductioninA1Cand
15mg/dLand20mg/dLreductionsinfast-
ing and 2-h postprandial glucose levels
(withevidenceofincreasedendogenousin-
sulin secretion in response to increase in
blood glucose, no change in body weight
but greater frequency of hypoglycemia)
(27); a similar study has been reported
with vildagliptin, a DPP-4 inhibitor that
is not available in the U.S. (28). A study
of 287 insulin-treated patients showed
that bile acid sequestrant colesevelam re-
duced fasting glucose and A1C, as well as
LDLcholesterol,butincreasedtriglyceride
levels (29). Morello concluded that MET
and TZD particularly reduce fasting glu-
cose, whereas postprandial glucose is bet-
ter reduced with DPP-4 and AGI, that
weight gain and hypoglycemia particu-
larly seem to complicate the addition of
insulin to TZD treatment, and that there
is some degree of favorable CV effect with
the addition of MET, whereas all of the
agents should be considered to have po-
tential adverse effects, such as MET caus-
inggastrointestinaleffectsandvitaminB12
deﬁciency and having renal contraindica-
tions, osteoporosis and ﬂuid retention
issueswithTZD,andpotentialgastrointes-
tinal side effects with AGI and bile acid
sequestrants,soappropriatepatientscreen-
ing and follow-up are essential.
In a study presented at the ADA
Scientiﬁc Sessions, Schwartz et al. (ab-
stract 564) administered the sodium-
glucose transporter (SGLT) 2 inhibitor
canagliﬂozin vs. placebo to 19 insulin-
treated diabetic patients, showing a 0.2
vs. 0.7% reduction in A1C from baseline
levels of 0.3%, with a 38 mg/dL decrease
vs. 9 mg/dL increase in fasting glucose.
Wilding et al. (abstract 021-LB) and
Parikh et al. (abstract 563) reported a
much larger study of 808 insulin-treated
type2diabeticpatientswithbaselineA1C
8.5% randomized to the SGLT2 inhibitor
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10 mg, or placebo, showing that no in-
sulin dose increase was required with
active treatment, with A1C decreasing
0.3% with placebo but 0.9% with 10 mg
dapagliﬂozin and with a weight loss of
1.7 kg in the latter group, suggesting the
potentialofthistreatmenttobeeffectively
added to insulin.
Wendy S. Lane (Asheville, NC) dis-
cussed the use of U-500 insulin therapy.
U-500 insulin is intermediate in onset of
action between regular and NPH insulin
(30), and in a study presented at the con-
ference, Jackson et al. (abstract 014-LB)
conﬁrmed the prolonged time to peak
effect and longer duration of action of
U-500 vs. human regular U-100 insulin.
Its use should be considered in patients
requiringhighdosesofinsulin,assugges-
ted by Lane, particularly in those requir-
ing.100units(andhencemorethanone
injection) per dose. Advantages include
improved insulin absorption, fewer (and
lower volume) injections to enhance
comfort and compliance, and, impor-
tantly, cost savings, with U-500 insulin
costing approximately $0.02/unit, less
than one ﬁfth the cost of insulin analogs.
Potential candidates include obese type 2
diabetic patients receiving multiple daily
doses of insulin, particularly after trans-
plant, or steroid treatment. Patients with
systemic infection or gestational diabetes
causing severe insulin resistance or pa-
tients with genetic and autoimmune de-
fects of insulin action also may beneﬁt
from such treatment (31).
Lane noted that there are relatively
few studies on this method of insulin
treatment, none randomized or con-
trolled. In a retrospective analysis of 20
patients whose treatment was changed to
U-500, A1C decreased from 9.6 to 8.5%
(32). In a study of nine patients followed
for 6 months, all gained weight (mean
4.7 kg), but A1C decreased from 10.3 to
7.9%, without signiﬁcant change in total
insulin dose (33). Lane discussed the
“off-label” use of U-500 administration
by insulin infusion pump, suggesting
that it be considered when the basal
insulin requirement exceeds 3 units/h. A
report of U-500 insulin administered by
pump to four patients noted reduction in
A1C from 10.8 to 7.6%. Two patients re-
quired reduction in total daily dose from
446 to 201 units, whereas the other two
had little change in dose (but improved
glycemia). Estimated cost savings per pa-
tient were $2,600 for insulin and $3,400
for pump supplies (34); such costs might
be twice as great today. A similar study of
six patients on insulin pumps reported a
decrease in daily insulin requirement
from 391 to 296 units per day, in A1C
from 9.1 to 6.9% and a weight loss of
6.1 pounds at 6 months, without clini-
cally signiﬁcant hypoglycemia (35). In
Lane’s study of nine patients receiving
U-500 insulin by infusion pump, A1C
decreased from 8.8 to 7.7% at 3 months
without increase in hypoglycemia (36);
she showed follow-up evidence of sus-
tained A1C reduction at 1 year. She re-
cently reported that, in a cohort of
21 patients receiving U-100 by infusion
pump when changed to U-500 in
12 months, A1C decreased by 1.2% from
8.9% with 71% increase in time spent in
euglycemia on continuous glucose moni-
toring (37). A suggestion for frequency
of U-500 administration is to convert
patients receiving 200–300 units/day to
U-500 twice daily, 300–750 units/day to
three times daily, 750–2,000 units/day
to four times daily, at doses exceeding
2,000 units/day to consider insulin
pump treatment (38). Lane emphasized
the potential for administration error and
suggested that, when used in hospital,
U-500 should be stored, dispensed, and
administered separately from U-100 insu-
lin, with its use highlighted in the medica-
tion record.
Matthew C. Riddle (Portland, OR)
discussed the use of GLP-1 agonists and
pramlintide with insulin, reviewing the
effectiveness and also limitation of pran-
dial and basal insulin and the potential
beneﬁts of basal insulin with an amylin
agonist or with a GLP-1 agonist. In the
Treating To Target in Type 2 Diabetes
(4-T) Study, three different approachesto
adding insulin to oral agents were com-
pared in 708 persons receiving MET plus
SUs (39). A1C decreased with all ap-
proaches, with basal-bolus approaches
reducing A1C from ;8.5 to 7%. Riddle
pointed out that all approaches using
prandial insulin are limited by the need
for frequent glucose testing and dose ad-
justment to address the complications of
weight gain and hypoglycemia, which
were least with an initial basal insulin ap-
proach. A1C can readily be reduced from
8.6 to 6.9% with either glargine or NPH
insulin at bedtime (40); however, Riddle
noted that the proportion of patients
achieving goal decreases with higher
starting levels, and even when A1C levels
are below 7%, there is quite a bit of post-
meal hyperglycemia (41), which Riddle
referred to as the “prandial problem,”
leading to a large subset of patients being
unable to achieve excellent control, with
titration of basal insulin limited by hypo-
glycemia.
He reminded the audience that amy-
lin and GLP-1 are secreted and that
glucagon and ghrelin are suppressed
postprandially (42,43), so that consider-
ation of use of agents mimicking and af-
fecting these systems may be relevant to
prandialglycemiccontrol.Hepointedout
that such treatment is currently “off-
label.”Amylintreatmentwithpramlintide
iscurrentlyapprovedinusewithprandial
insulin. In a 24-week study of 113 obese
patients with baseline A1C 8.4% on oral
agents and basal insulin, the latter titrated
to ;45 units/day, those randomized to
prandial rapid-acting insulin received
;12 units before each meal and were
comparedwith agroup given pramlintide
before meals. A1C decreased by 1.1 and
0.9%, the 90-min postprandial glucose
increment was similar, and weight in-
creased 4.2 kg vs. decreasing 0.3 kg, re-
spectively (44). Exenatide is approved for
use as monotherapy or in combination
with MET, SU, or TZD as a twice daily
injection. Riddle presented results of a
24-week study of 34 patients not easily
controlled with oral agents with or with-
out basal insulin, treated with insulin
glargine plus MET, and randomized to
exenatide vs. placebo twice daily (Riddle
et al., abstract 18-LB). The baseline BMI
was 34 kg/m
2, both groups were titrated
to 0.5 units/kg glargine, and fasting glu-
cose fell similarly from ;165 to 120 mg/
dL; however, there was a nearly signiﬁ-
cant difference in A1C decrease from 8.0
to 7.3% with placebo and from 7.9 to
6.5% with exenatide, with similar fre-
quency of hypoglycemia and with weight
increasing by 4 kg with placebo but no
weight change with exenatide. Continu-
ous glucose monitoring at the end of the
study showed that glycemic excursions
after breakfast and dinner were consider-
ably less with exenatide, although levels
increasedsimilarlyafterlunch,suggesting
that if exenatide was to be administered
three times daily, a greater glycemic
effect would be observed. Riddle also
reviewed a 259-patient study presented
at the meeting that compared the addition
of exenatide vs. placebo with insulin glar-
gine treatment in type 2 diabetic patients
with a baseline BMI of 33. Insulin was ti-
trated from 50 to 62 units/day vs. from 47
to 69 units/day, whereas fasting glucose
decreased from 142 to 116 vs. 149 to
118 mg/dL. There was, however, greater
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to 6.7 vs. 8.5 to 7.4%, greater improve-
ment in a seven-point glucose proﬁle,
and a weight loss of 1.8 kg vs. weight
gain of 1 kg, respectively (Buse et al., LB-
10). Riddle concluded that gastrointestinal
peptide-related treatments offer mecha-
nisms beyond insulin for control of pran-
dialglycemia,inafashionthat reduces the
likelihood of hypoglycemia and weight
gain. Whether other amylin and incretin
agonists will have similar effects, whether
there is heterogeneity in patient respon-
siveness to such regimens, and whether
these approaches will improve medical
outcome are not known.
A number of studies presented at the
ADA conference also addressed combina-
tion treatment with insulin. Ellis et al.
(abstract 9-LB) reported an effect of sita-
gliptinonglucose controlinpatients with
type 1 diabetes, with 0.3% reduction in
A 1 C ,a n d1 1m g / d Ld e c r e a s ei nm e a n
glucoseoncontinuousmonitoring.Zinman
et al. (abstract 40) treated 182 patients
with type 2 diabetes with MET plus in-
sulin glargine or with insulin degludec
three times weekly or daily for 16 weeks,
titratingtofastingglucose113–116mg/dL,
with insulin doses of 0.45–0.49 units/
kg/day given at bedtime; A1C decreased
from 8.7 to 7.2, 8.8 to 7.3, and 8.7 to
7.4%,respectively.Gallwitzetal.(abstract
557) randomized 354 MET-treated pa-
tients to the addition of exenatide vs. in-
sulinaspartofaﬁndingsimilarto0.9vs.
1.0% A1C reduction from baseline
7.9%,butwith8vs.21%developinghy-
poglycemia and weight loss of 4.1 kg vs.
gain of 1.0 kg; adverse gastrointestinal
effects occurred more commonly with
exenatide.
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